FULL PDF
Abstract
The development of novel organic compounds for cancer therapeutics is a cornerstone of pharmaceutical innovation. However, the patenting of these compounds faces numerous challenges due to legal and scientific complexities. In the field of anticancer drug discovery, patenting new chemical entities (NCEs) is increasingly difficult, as prior art accumulates and the standards for novelty and non-obviousness become more stringent. This paper specifically examines the patenting challenges faced by pharmaceutical companies in the development of novel anticancer organic compounds, focusing on the legal complexities surrounding novelty, prior art, patent lifecycle management, and the regulatory approval process. Through a detailed analysis of recent patent disputes and industry trends, this paper provides actionable insights into the evolving patent landscape for anticancer drugs, proposing solutions to facilitate innovation while ensuring public access to life-saving therapies.
View more >>